Acetohexamide

From Wikipedia, the free encyclopedia


Acetohexamide
Systematic (IUPAC) name
1-(4-acetylphenyl)sulfonyl-3-cyclohexyl-urea
Identifiers
CAS number	968-81-0
ATC code	A10BB31
PubChem	1989
DrugBank	APRD00773
Chemical data
Formula	C₁₅H₂₀N₂O₄S
Mol. mass	324.396 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	90%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Acetohexamide (Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.

[edit] Mechanism of Action

Acetohexamide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. For this reason, acetohexamide is not used to treat diabetes mellitus type 1.

[edit] Risks

Oral hypoglycemic drugs, including acetohexamide, have been associated with increased cardiovascular mortality. Talk to your doctor about the possible risks, benefits, and alternatives of using this drug for your condition ^[1].

[edit] References

^a Medline Plus - Acetohexamide

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)

Biguanides	Metformin

Sulfonylureas	Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide

Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose

Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡

Meglitinides	Nateglinide, Repaglinide, Mitiglinide

Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin

Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†

Amylin analog	Pramlintide

Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera)

Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§

SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†, Sergliflozin^†

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.